Renalytix (LON:RENX) Trading Up 4.8% – Should You Buy?

Renalytix Plc (LON:RENX) shot up 4.8% during mid-day trading on Wednesday . The stock traded as high as GBX 11 ($0.14) and last traded at GBX 11 ($0.14). 240,993 shares changed hands during mid-day trading, a decline of 44% from the average session volume of 432,985 shares. The stock had previously closed at GBX 10.50 ($0.13).

Renalytix Stock Up 4.8 %

The stock’s 50 day moving average is GBX 8.45 and its 200 day moving average is GBX 10.57. The company has a market capitalization of £18.25 million, a PE ratio of -45.83 and a beta of 2.10. The company has a debt-to-equity ratio of 173.95, a quick ratio of 2.42 and a current ratio of 0.53.

Insider Buying and Selling at Renalytix

In other news, insider James Renwick McCullough acquired 25,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was bought at an average cost of GBX 9 ($0.11) per share, for a total transaction of £2,250 ($2,815.32). Also, insider Christopher H. B. Mills sold 83,696 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of GBX 8 ($0.10), for a total transaction of £6,695.68 ($8,377.98). Insiders own 35.74% of the company’s stock.

Renalytix Company Profile

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S.